



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



Vascular Endothelial Growth Factor-165, human recombinant (rHuVEGF-165)

Catalog No: 87399
Lot No: XXXXX
Source: *E. coli*
Synonyms: Vascular endothelial growth factor A, VEGF-A, Vascular permeability factor, VPF, VEGF, MGC70609

Background

Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis and angiogenesis. As its name implies, VEGF activity has been mostly studied on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g. stimulation monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). VEGF mediates increased vascular permeability, induces angiogenesis, vasculogenesis and endothelial cell growth, promotes cell migration, and inhibits apoptosis. In vitro, VEGF has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor. Elevated levels of the VEGF protein are linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in the VEGF gene have been associated with proliferative and nonproliferative diabetic retinopathy.

Description

Vascular Endothelial Growth Factor human recombinant produced in *E. coli* is a double, non-glycosylated, polypeptide chain containing 165 amino acids and having a molecular mass of 38231 Dalton. VEGF is purified by proprietary chromatographic techniques.

Physical Appearance

Sterile filtered white lyophilized (freeze-dried) powder.

Formulation

The VEGF protein was lyophilized from a concentrated (1 mg/ml) solution with no additives.

Solubility

It is recommended to reconstitute the lyophilized VEGF in sterile 18 M Ω -cm H₂O not less than 100 μ g/ml, which can then be further diluted to other aqueous solutions.

Stability

Lyophilized VEGF, although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution VEGF should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

Purity

Greater than 95.0% as determined by (a) Analysis by RP-HPLC, (b) Analysis by SDS-PAGE.

Amino Acid Sequence

APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI
MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC
DKPRR



Activity

VEGF activity was determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 3.7 – 5.6 ng/ml, corresponding to a specific activity of 178,570 – 270,270 IU/mg.

Usage

This product is offered by Biomol for research purposes only. Not for diagnostic purposes or human use. It may not be resold or used to manufacture commercial products without written approval of Biomol GmbH.